Evidence map›Paper›PMID 40663626›Full record

ArticleScience signaling2025

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung, Kent Gorday, Emily Sumpena, Wenqi Zuo, Jay T Groves, Brian J Druker, John Kuriyan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science signaling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Serena MuratciogluDepartment of Biochemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-5983-294X
Christopher A EideDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-8835-8928
Chien-Lun HungDepartment of Biochemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-2546-1132
Kent GordayBiophysics Graduate Group, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-9092-9782
Emily SumpenaDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID 0009-0003-7701-0821
Wenqi ZuoDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID 0009-0004-8752-0275
Jay T GrovesDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-3037-5220
Brian J DrukerDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-8331-8206
John KuriyanDepartment of Biochemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-4414-5477

Funding

Understand the metabolic fitness of naïve T cellsP01AI091580 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEROEN ROOSE · 2011 to 2026
$31.1M
NIAID NIH HHS P01 AI091580
6 · The paper itself

Abstract

Chromosomal translocations that fuse

Indexed as

Drug Resistance, NeoplasmFusion Proteins, bcr-ablLymphocytesOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-ablAllosteric RegulationHumansNiacinamidePhosphorylationPyrazolesasciminibFusion Proteins, bcr-ablNiacinamideOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazoles

Identifiers

PMID40663626
PMCPMC12313245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.